Furuta Akira, Asano Koji, Egawa Shin, de Groat William C, Chancellor Michael B, Yoshimura Naoki
Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
J Urol. 2009 Mar;181(3):1467-73. doi: 10.1016/j.juro.2008.11.008. Epub 2009 Jan 20.
We investigated the role of alpha(2)-adrenoceptors and glutamate mechanisms in the urethral continence reflex in response to abdominal pressure increases.
Under urethane anesthesia external urethral sphincter electromyogram activity was evaluated in spinal cord transected (T8-T9) female rats during lower abdominal wall compression before and after intravenous application of test drugs. The effects of the N-methyl-D-aspartate glutamate receptor antagonist MK-801 (Sigma) or the alpha(2)-adrenoceptor agonist medetomidine (Tocris Cookson, Ellisville, Missouri) (each 0.03, 0.3 and 3 mg/kg intravenously) on external urethral sphincter activity were examined. A 0.3 mg/kg intravenous dose of the alpha(2)-adrenoceptor antagonist idazoxan (Sigma) was then administered before or after the application of 1 mg/kg MK-801 intravenously. In addition, 0.3 mg/kg idazoxan were administered intravenously following the application of 1 mg/kg of the serotonin/norepinephrine reuptake inhibitor duloxetine (Kemprotec, Middlesbrough, United Kingdom) intravenously.
MK-801 and medetomidine dose dependently decreased external urethral sphincter activity. Idazoxan significantly increased external urethral sphincter activity by 64% but the increase in activity after idazoxan was abolished by MK-801. On the other hand, idazoxan did not reverse the inhibitory effects of MK-801. In addition, idazoxan significantly potentiated the duloxetine effects on external urethral sphincter activity by 120%.
These results indicate that 1) glutamate is a major excitatory neurotransmitter in the urethral continence reflex response to abdominal pressure increases, 2) alpha(2)-adrenoceptor activation suppresses external urethral sphincter activity, probably via presynaptic inhibition of glutamate release and 3) the effects of serotonin/norepinephrine reuptake inhibitors are enhanced by alpha(2)-adrenoceptor inhibition. Therefore, alpha(2)-adrenoceptor antagonists could be beneficial for treating stress urinary incontinence.
我们研究了α₂肾上腺素能受体和谷氨酸机制在腹压增加时尿道控尿反射中的作用。
在乌拉坦麻醉下,对脊髓横断(T8 - T9)的雌性大鼠,于静脉注射受试药物前后,在下腹壁受压期间评估其尿道外括约肌肌电图活动。检测N - 甲基 - D - 天冬氨酸谷氨酸受体拮抗剂MK - 801(西格玛)或α₂肾上腺素能受体激动剂美托咪定(Tocris Cookson公司,密苏里州埃利斯维尔)(静脉注射剂量分别为0.03、0.3和3毫克/千克)对尿道外括约肌活动的影响。然后在静脉注射1毫克/千克MK - 801之前或之后,静脉注射0.3毫克/千克的α₂肾上腺素能受体拮抗剂咪唑克生(西格玛)。此外,在静脉注射1毫克/千克的5 - 羟色胺/去甲肾上腺素再摄取抑制剂度洛西汀(Kemprotec公司,英国米德尔斯堡)之后,静脉注射0.3毫克/千克咪唑克生。
MK - 801和美托咪定均剂量依赖性地降低尿道外括约肌活动。咪唑克生使尿道外括约肌活动显著增加64%,但MK - 801消除了咪唑克生后的活动增加。另一方面,咪唑克生并未逆转MK - 801的抑制作用。此外,咪唑克生使度洛西汀对尿道外括约肌活动的作用显著增强120%。
这些结果表明,1)谷氨酸是腹压增加时尿道控尿反射中的主要兴奋性神经递质,2)α₂肾上腺素能受体激活可能通过对谷氨酸释放的突触前抑制来抑制尿道外括约肌活动,3)α₂肾上腺素能受体抑制增强了5 - 羟色胺/去甲肾上腺素再摄取抑制剂的作用。因此,α₂肾上腺素能受体拮抗剂可能对治疗压力性尿失禁有益。